Sonoma Pharmaceuticals Announces New CE Marking for Microdacyn60 Eye Care
Sonoma Pharmaceuticals has announced that it received a new CE Marking for its Microdacyn60 eye care based on Sonoma’s patented Microcyn Technology.
The formulation, marketed in the United States as Acuicyn Antimicrobial Eyelid and Eyelash Hygiene solution, is a safe and efficacious method to keep areas around the eye and eyelids/eyelashes clean and remove foreign materials, according to a company news release. Sonoma’s performance-stabilized hypochlorous acid (HOCl), which is at the heart of Acuicyn and Microdacyn60 eye care, can be used safely around eyes, ears, nose and mouth without concerns about toxicity or stinging.
Sonoma also announced that it has agreed on a new 10-year license, distribution and supply agreement with its distribution partner Brill International S.L. to market the eye care product under the private label Ocudox in the European markets of Italy, Germany, Spain, Portugal and the United Kingdom, subject to Brill meeting certain annual minimum purchase requirements. Previously, Sonoma’s partnership with Brill covered only the Spanish and Portugese markets.
“We are pleased by the reaffirmation of our patented Microcyn Technology products by the European Union,” Amy Trombly, CEO of Sonoma, said in the news release. “Our powerful Microcyn technology has many applications treating a wide range of symptoms and conditions. We are excited to take our partnership with Brill to the next level and increase our eye care presence in Europe.”
Ocudox is expected to become available in Italy, Germany and the United Kingdom in a phased rollout over the next 12 months.